Last reviewed · How we verify
NCT05472688
My Baby Biome: Infant Stool Samples for Microbiome Health (MBB)
trial in Dysbiosis in 430 participants. Participants enrolled and being followed up; not accepting new ones.
31 March 2023
Quick facts
| Lead sponsor | Persephone Biosciences |
|---|---|
| Status | Active, enrolled |
| Study type | OBSERVATIONAL |
| Enrollment | 430 |
| Start date | 14 July 2022 |
| Primary completion | 31 March 2023 |
| Estimated completion | 31 December 2029 |
| Sites | 1 location across United States |
Conditions studied
- Dysbiosis — all drugs for Dysbiosis →
Sponsor
Persephone Biosciences
Who can join
Adults 0 Months to 2 Months, any sex, with Dysbiosis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
My Baby Biome is an observational study that will use 600 infant stool samples to determine the biomarkers associated with a healthy infant gut. Biomarkers identified in this study will be used to develop precision probiotics and LBPs for improving infant gut health outcomes to the benefit of all infants. Parents will be asked to submit follow-up questionnaires regarding infant immune health to improve insights obtained from the data.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Bifidobacterium deficit in United States infants drives prevalent gut dysbiosis.
Jarman JB, Torres PJ, Stromberg S, Sato H, et al · · 2025 · cited 11× · PMID 40555747 · DOI 10.1038/s42003-025-08274-7
Verify or expand the search:
- PubMed search for NCT05472688
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Dysbiosis
Currently open trials in the same condition.
- NCT07148583 — BioAmicus Complete for Functional Gastrointestinal Symptoms in Infants Aged 0 to 24 Months · NA · recruiting
- NCT07231003 — The Effect of Glucomannan Powder on Improving Gut Microbiota. · NA · active not recruiting
- NCT06877585 — Association Between Fecal Microbiota Composition, Metabolite Concentrations, and Indoxyl Sulfate Levels · recruiting
- NCT06872320 — The Influence of Probiotics on Metabolome and Heart Rate Variability in Heart Failure of Structure Heart Disease · NA · active not recruiting
- NCT06914375 — Effect of Lentils and Chickpeas on Gut Microbiome and Metabolic Health · NA · active not recruiting
Other Persephone Biosciences trials
Trials by the same sponsor.
- NCT06746285 — Evaluating the Impact of Synbiotic Supplementation on Infants and Toddlers · NA · active not recruiting
- NCT06091813 — Ambrosia: Evaluating the Effects of a Food-As-Medicine Platform on Gut Microbiome Composition and Metabolism · NA · completed
- NCT04638751 — ARGONAUT: Stool and Blood Sample Bank for Cancer Patients · recruiting
- NCT04770649 — Vaccine Observation to Include All Communities for Equitable Science · terminated
- NCT04291755 — Development and Analysis of a Stool Bank for Cancer Patients · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05472688 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Persephone Biosciences
- Last refreshed: 5 April 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05472688.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing